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OBJECTIVE—Althoughtype1diabetesautoimmunityfrequentlybeginsinchildhood,littleis
known about the relationship between age and autoimmunity development. Our aim was to
determinethetimingofseroconversiontodiabetes-associatedautoantibody(DAA)positivityand
risk in ﬁrst- and second-degree relatives of patients with type 1 diabetes.
RESEARCH DESIGN AND METHODS—Study subjects were identiﬁed through the
Diabetes Prevention Trial-Type 1 (DPT-1). Children 3–18 years of age (n = 42,447) were
screened for DAAs; 1,454 were ICA positive ($10 JDF units), 1,758 were GAD65 positive,
and 899 were ICA512 positive at the time of initial screening. Subjects who were initially anti-
body negative (n = 39,212) were recalled for rescreening, and 11,813 returned for rescreening.
RESULTS—DAA seroconversion occurred in 469 (4%) children; 258 seroconverted to ICA,
234 to GAD65, and 99 to ICA512. The median time to seroconversion was 2 years. The 2-year
risk for DAAs was highest in early childhood. For each 1-year increase in age in this cohort, the
risk of any autoantibodyseroconversion (HR0.95,95% CI 0.92–0.97) decreased by 5%, and for
any two autoantibodies risk decreased by 13% (0.87, 0.82–0.93).
CONCLUSIONS—Risk of autoantibody seroconversion among children followed in DPT-1
is age dependent. Younger children have the highest risk for DAAs, with the majority of children
seroconverting by 13 years of age (75%). This suggests that annual screenings should be started
inearlychildhoodandcontinuedthroughearlyadolescencetoidentifythemajorityofsubjectsat
risk for type 1 diabetes and eligible for prevention trials.
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t is well known that the presence of
islet autoantibodies increases the risk
of type 1 diabetes (1,2). The known
diabetes-associated autoantibodies (DAAs)
associated with type 1 diabetes include
cytoplasmic islet cell (ICA), insulin
(IAA,microIAA [mIAA]),65-kDaisoform
of glutamic acid decarboxylase (GAD-65,
GADA, GAA), and insulinoma-associated
protein 2 (IA-2, IA-2A, ICA512). These
autoantibodies usually precede type 1 di-
abetes onset and are regularly used as in-
dicators to identify the preclinical period
of the disease. Autoimmunity screening for
DAAs is useful in identifying individuals
withincreasedrisk oftype1 diabetes(1,3).
A limited number of previous studies
have suggested the need for autoanti-
body rescreening but have been limited
in their ability to extensively describe the
natural history of seroconversion through-
out childhood. Colman et al. (4) demon-
strated that 3.4% of children with an
affected ﬁrst-degree relative who screened
negative for islet autoantibodies in early
childhood (,8 years of age) later screened
positive at a mean age of 11 years; thus,
reliance ona single screening effortinearly
childhood would have failed to identify a
considerable portion of genetically at-risk
children who seroconverted after 8 years
of age. They concluded that screening
should be performed more than once be-
fore puberty.
The importance of understanding the
relationship between age and the onset of
autoimmunity provides valuable insight
regarding preclinical type 1 diabetes
screening; ﬁrst, to determine if there is
an optimal age window(s) to screen for
autoantibodies; second, to determine the
timing of the onset of autoimmunity
relative to environmental exposures so
as to potentially identify mechanisms
involved in the disease; and, third, to
identify patients for prevention trials.
This work assessed the characteristics of
DAAs, yield of screening efforts, and the
risk of ﬁrst autoantibody development
and multiple autoantibody development
by age.
RESEARCH DESIGN AND
METHODS—All subjects were par-
ticipants in the screening cohort of the
DPT-1 study (5) who were screened for
the presence of ICAs between February
1994 and October 2002 for potential
study accrual to delay or prevent type 1
diabetes. The current study group was
comprisedofﬁrst-andsecond-degreerel-
atives of patients with type 1 diabetes (3–
18yearsofage)whoscreenednegativefor
all DAAs (ICA, ICA512, GAD65, and
mIAA) at their ﬁrst screening and re-
turned for a rescreening. mIAA was mea-
s u r e do na l ls u b j e c t sa tt h e i ri n i t i a l
screening and used as inclusionary crite-
ria to determine autoantibody-free status;
thereafter, mIAA was only measured on a
small proportion of the DAA-negative sub-
jects at rescreening. Thus, this study did
not assess risk for mIAA. Autoantibody-
negative subjects were rescreened at sub-
sequent visits for ICA, ICA512, and
GAD65. For all other DAAs, those aged
3–10yearswererescreenedannually,and
those aged .10 years were screened bien-
nially. Approximately 30% of this popula-
tion had at least one or more autoantibody
rescreening.
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ICA values were determined using the
standard indirect immunoﬂuorescence
method using cryo-cut sections of frozen
sections of human pancreas at the DPT-1
ICA core laboratory (Gainesville, FL, and
N e wO r l e a n s ,L A ) .T i t e r s$10 Juvenile
Diabetes Foundation units (JDFU) were
considered positive for ICA. The ICA as-
says had a speciﬁcity of 100% with a sen-
sitivity of 74.4% (6).
GAD65, ICA512, and mIAA
GAD65 and ICA512 were determined at
the Barbara Davis Center in Denver,
Colorado, and measured simultaneously
by combined GAD65 and ICA512 radio-
assay as previously described (full-length
GAD65 and ICA512bdc cDNA clones)
(7). The assay was performed in 96-well
ﬁltrationplateswithautoantibody-bound
[
3H]GAD65 and [
35S]ICA512 precipi-
tated with protein A-Sepharose. The cut
points were set at indices of $0.032
(GAD65) and $0.049 (ICA512A). The
interassay coefﬁcients of variation (CV)
were 6.5% and 9.6%, respectively. This
assay had a speciﬁcity of 99% and a sen-
sitivity of 83.7% in subjects #30 years of
age with new-onset type 1 diabetes in the
IDS Combinatorial Autoantibody Work-
shop (6). IAA values, using the microvol-
ume requiring assay, were determined at
the Barbara Davis Center or the Joslin Di-
abetes Center (Boston, MA) (8). The sen-
sitivity for the mIAA assay was 74%/56%,
and the speciﬁcity was 90%/98% for the
Denver and Boston laboratories. The cor-
relation coefﬁcient between both labora-
tories was r = 0.90, P , 0.0001, and the
interassay CV was 16%.
The protocol was approved by the
institutional review boards at participat-
ing locations, and all participants pro-
vided written informed consent.
Statistical analysis
Data were analyzed using the SAS soft-
ware (version 9.2; SAS Institute, Cary,
NC). Categorical variables were analyzed
using Pearson x
2 tests. Continuous varia-
blesweretestedusing ttestfordifferences
in means or Wilcoxon rank-sum test for
differences in medians. Autoantibody se-
roconversion was deﬁned as the ﬁrst pos-
i t i v es a m p l ef o ras p e c i ﬁc autoantibody.
Cox proportional hazards models for an
open cohort design were used to estimate
2-year risks for seroconversion and to de-
termine signiﬁcant predictors of serocon-
version. Two-year risk estimates were
chosen based on median follow-up time
inthiscohort.Efron’smethodfortiedsur-
vival times were used in the Cox analysis
(9). Selection of variables for the ﬁnal
model was accomplished by removing
nonsigniﬁcant effects in a stepwise fash-
ion. Entry and exit levels were at 5%. The
assumption of constant hazard function
was assessed by examining the log cumu-
lative survival plots.
RESULTS—Characteristics of the study
population by DAA development are
presented in Table 1. Of the 42,447 sub-
jects aged 3–18 years screened for DAAs
in the DPT-1 Study, 3,235 subjects
(7.6%) were autoantibody positive at the
time ofinitial screening.Ofthese, (Table2,
ﬁrst column) 1,454 subjects (3.4%) were
ICA positive, 1,758 (4.1%) were GAD65
positive,899(2.1%)wereICA512positive,
and 1,094 (2.6%) were mIAA positive. At
the initial screen, 39,212 subjects were
autoantibody negative. There was no sig-
niﬁcant difference in age (P = 0.2964) or
race/ethnicity (P = 0.0798) between the
two groups (DAA+ vs. DAA2). There
were small proportional differences be-
tween sexes (P =0 . 0 0 8 )( T a b l e1 ) ,a n d
there was a signiﬁcantly higher propor-
tion of siblings of patients with type 1 di-
abetes (P , 0.0001) in children positive
for an autoantibody.
For those DAA negative at the initial
screen and who returned for at least one
rescreening (n = 11,813), 469 (4.0%) se-
roconverted to DAA(s) positive, 258
(2.2%) to ICA positive, 234 (2.0%) to
GAD65 positive, and 99 (0.8%) to
ICA512positive(Table2).Thesechildren
were signiﬁcantly younger (P , 0.0001)
in median age (years [quartile 1–quartile
3]) at the initial screen (7.1 years [5.1–
10.0] vs. 8.2 years [5.5–11.6]) compared
with the remaining children who did not
seroconvert (n = 11,344). Median (Q1–
Q3) time of follow-up for those who re-
turned for a rescreening in the study was
27.1 months (20.1–49.1). There were no
differences in race (P = 0.39), relation to
proband (P =0 . 1 1 ) ,o rs e x( P =0 . 4 2 )
among those who seroconverted and
those that remained autoantibody nega-
tivethroughoutfollow-up.Fifty-fourper-
cent (n = 251) of the children who
seroconverted did so by 11 years of age,
with 75% seroconversion by 13 years of
age. There was nosigniﬁcantdifferencein
the number of rescreens for those who
seroconverted #10 versus .10 years of
age (P = 0.76).
DAAs had varying patterns of pre-
sentation in those children who serocon-
verted. Median ages at seroconversion
(years[Q1–Q3])weresimilarwiththeex-
ception that children seroconverted to
GAD65 at a signiﬁcantly younger age
than to ICA (P = 0.02) (GAD65, 9.5 years
[7.1–12.6]; ICA, 10.2 years [8.2–13.7];
and ICA512, 9.9 years [7.3–13.5]). For
those individuals who developed multi-
ple autoantibodies, GAD65 seroconver-
sion generally occurred earlier than ICA
orICA512,withICAseroconversionusu-
ally occurring after ICA512. If a child
tested positive for two DAAs at the same
testing, it was likely a combination of
GAD65 and ICA512, as the timing of
each of these DAAs generally preceded
the occurrence of ICA, giving rise to two
positive autoantibodies.
Table 1—Characteristics of the screened population aged 3–18 years
Ab2 at initial
screening
Ab+ at initial
screening P
Total (N) 39,212 3,235
Age at initial screen (years) 9.7 (6.3–13.2) 9.8 (6.6–13.2) 0.2964
Sex (% female) 47% 49% 0.0079
Race (%) 0.0798
White 82 84
Black 3 2
Hispanic 12 11
Other 1 1
Unknown 2 2
Relationship to index patient with type 1
diabetes (%)
,0.0001
Sibling 45 52
Offspring 28 27
Second-degree relative 27 21
Data are median (Q1–Q3) and percent unless otherwise indicated.
care.diabetesjournals.org DIABETES CARE, VOLUME 34, FEBRUARY 2011 359
Vehik and AssociatesThe 2-year risk for seroconversion by
age showed signiﬁcant decreases (P ,
0.001) with increasing age for all DAAs
(Fig. 1). GAD65 2-year risk had a signif-
icantly different slope of decline com-
pared with ICA512 (P , 0.0001) and
ICA (P , 0.0001) across all ages, with
GAD65 risk having a steeper slope for
those aged 6 years and under. ICA risk
was signiﬁcantly higher than ICA512
risk for all ages (P = 0.003). The 2-year
risk for any DAA was signiﬁcantly (P ,
0.0001)higheracrossallagesthanforany
two DAAs.
Using Cox proportional hazards
models, the age at initial screening
was identiﬁed as a signiﬁcant predictor
for risk of autoantibody seroconversion
for all autoantibodies (ICA, P =0 . 0 1 ;
ICA512, P = 0.004; GAD65, P ,
0.0001). In univariate models, siblings
had a 46% (HR 1.46, 95% CI 1.06–2.03)
greater risk ofGAD65seroconversion (P =
0.02), and females had 21% (0.79, 0.64–
0.98) lower risk of ICA seroconversion
(P = 0.03). Race/ethnicity was not a signif-
icantpredicatorforautoantibodyserocon-
version in this cohort. In multivariable
models adjusted for race, sex, relation to
index proband, and rescreen interval, age
at initial screening was the primary pred-
icator of autoantibody seroconversion for
any DAA (P , 0.0001). The risk of DAA
seroconversion greatly increased if the
subject was already positive for another
autoantibody. DAA seroconversion risk
signiﬁcantly decreased with increasing
age for GAD65 (HR 0.90, 95% CI 0.87–
0.93, P , 0.0001), ICA (0.96, 0.93–0.99,
P = 0.01), and ICA512 (0.92, 0.87–0.98,
P = 0.004). For each 1-year increase in age
inthiscohort,theriskofanyautoantibody
seroconversion (0.95, 0.92–0.97, P ,
0.0001) decreased by 5% and for two au-
toantibodies risk decreased by 13% (0.87,
0.82–0.93, P , 0.0001).
Lastly, 69 (15%) of the 469 that
seroconverted during rescreening devel-
oped multiple autoantibodies. Of the 69,
45 (65%) seroconverted to multiple auto-
antibodies at the same screening and 24
(35%)developedmultipleautoantibodies
over time. Twenty-four of the 469 sub-
jects (5%) who DAA seroconverted de-
veloped type 1 diabetes. At the time of
diagnosis, 8% were ICA positive only, 4%
wereGAD65positiveonly,4%wereGAD65
and ICA512 positive, 17% were ICA and
GAD65 positive, 21% were ICA512
and ICA positive, and 45% were positive
for all three autoantibodies. There were
19 subjects that developed type 1 diabetes
who had no autoantibodies at the last
screening before diagnosis (median was
15 months prior to diagnosis). The me-
dian age (Q1–Q3) at type 1 diabetes diag-
nosis was 12.4 years (9.7–14.7).
CONCLUSIONS—Autoantibody se-
roconversion rates are age-dependent
among the ﬁrst- and second-degree rela-
tives of type1 diabeticprobands followed
through childhood and adolescence in
the DPT-1, with a declining seroconver-
sion rate with increasing age. Although,
the risk of seroconversion for DAAs has
been reported to be greatest in early life
(,10 years) (10), risk of seroconversion
exists throughout childhood and adoles-
cence. While not in direct conﬂict with
Colman et al. (4), the DPT-1 cohort pro-
vided additional information to possibly
augment their recommendations to
screen more than once before puberty.
GAD65 and ICA had the highest 2-
year seroconversion risks, with GAD65
carrying a greater risk for those in early
childhood(#6 yearsof age).Seventy per-
cent of those DAA positive in this cohort
were identiﬁed at the initial screen, and
rescreening efforts were successful at
identifying an additional 10% of the ex-
pected 30% likely to seroconvert in the
DAA-negative cohort. Of all the DAA-
negative subjects eligible for rescreening
(n = 39,212), the subjects that returned
for rescreening (n = 11,813) were similar
to the subjects that did not return for re-
screening (n =27,399)regarding age,sex,
race,andrelationtoproband.Byapplying
the absolute rate of seroconversion (469/
11,813) to the entire negative cohort, an
estimated 1,557 subjects would have
likely seroconverted during the follow-
up period. The initial screen identiﬁed
3,235 (70%) of the estimated 4,792 sub-
jects likely to have seroconverted if the
entire cohort was rescreened during the
follow-upperiod.Theestimatedcostfora
DAAscreen(includingallautoantibodies)
is $70. Therefore, the initial screen cost
per seroconversion was an estimated
$918 ($70for eachof the 42,447subjects
at initial screen) to identify 70% of those
who were DAA-positive versus $1,763
($70 for each of the 11,813 subjects re-
screened) for the remaining 10% (n =
469) that were identiﬁed through the
DPT-1 rescreening effort.
Although economic realities may
limit the ability to continually rescreen,
strategies designed to capture those at
highest risk are needed with the rapidly
increasing incidence of type 1 diabetes
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Justiﬁcation for islet autoantibody rescreeningworldwide and the highest observed an-
nual rates in the youngest age-group
(5.4% [4.8–6.1] for children age 0–4
years) (11). The DPT-1 cohort data
show that the majority of those that sero-
converted were among the youngest and
had the highest 2-year risk. As such, if we
aim to identify the majority of subjects at
risk for type 1 diabetes, it is necessary to
continue screening for DAAs in early
childhood, whereas screening in late ad-
olescence and early adulthood will likely
identify those with late-stage b-cell de-
cline in whom therapy is not as effective.
B a s e do nt h e s eﬁndings, annual rescreen-
ing for autoantibody seroconversion in
relatives of type 1 diabetic probands is
suggested for those in early childhood
and adolescence and only once in late ad-
olescence.Thisstrategyismorecosteffec-
tive to optimize identiﬁcation of subjects
at risk for DAAs and eligible for participa-
tion in prevention trials.
Despite the important and novel ob-
servations described, this study’sm a i n
limitation was that timing of rescreening
was not uniform across subjects. Subjects
3–10 years of age were rescreened annu-
ally, whereas subjects .10 years of age
were rescreened biennially. Therefore,
timing to seroconversion for those older
than 10 years of age could occur anytime
during a 2-year window. This difference
in the screening interval for those .10
years of age could potentially underesti-
mate the risk, where the time to DAA se-
roconversion could be a year earlier than
observed. However, after assessment of
theimpactofthispotentialbiasbyadjust-
ing for the screening cycle difference, age
continued to be signiﬁcantly associated
with DAA seroconversion independent
of the screening cycle. Also, it is likely
the 2-year risks of DAA seroconversion
may be underestimated because of the
median age at initial screening in this co-
hort (;10 years); however, this provided
additional support to initiate screening
strategies earlier in life. Additionally,
IAA seroconversion was not evaluated in
this study because of limited measures on
only a very small proportion of those re-
screened.Thislimitationmaybeapparent
in assessing risk for type 1 diabetes devel-
opment, since IAAs have been shown to
be a signiﬁcant indicator of risk, as have
ZnT8 autoantibodies. Lastly, this study
was not able to assess risk for type 1
diabetes because of limitations in type 1
diabetes development follow-up on the
screened population in the DPT-1.
Although many studies have assessed
the presence of autoimmunity in type 1
diabetic high-risk subjects, the data have
been limited in assessing screening strat-
egies for type 1 diabetes autoimmunity.
Understanding the etiology of the pre-
clinical period of diabetes by determining
the time of autoantibody seroconversion
may assist in identifying potential envi-
ronmental triggers associated with the
etiology of islet autoimmunity.
This study provides evidence that the
rate of autoantibody seroconversion de-
clines with age, varies throughout child-
hood and adolescence, and extends into
earlyadulthood.Thoseinearlychildhood
have the highest 2-year risk for any DAA
seroconversion (2.7% at 3 years), while
the risk declines further from 1.8% at
10 years to 1.2% for those over 16 years
of age. These ﬁndings suggest starting
screening in early childhood for those at
increased risk (i.e., those with a relative
with type 1 diabetes) and screening an-
nually for all DAAs (including ZnT8
autoantibodies and IAAs not measured
Figure 1—Two-year risk of autoantibody seroconversion by autoantibody and development of any autoantibody(s) by age (years). GAD65, gray
dashed line; ICA, solid black line; ICA512, black dashed line; any autoantibody, black dotted line; and any two autoantibodies, solid gray line.
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Vehik and Associatesin this study) through early adolescence
to capture the majority of those at risk for
diabetes autoimmunity.
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